Facilitators and Barriers of Exercise Rehabilitation Programs Implementation in Coronary Heart Disease Patients: A Mixed Method Systematic Review.

J Cardiovasc NursNov 25, 2025 (epub)
Clinical ResearchCardiology

Tian Yu, Wang Yingjie, Sun Xiaoting et al.

✦ AI-curated · Sources linked

In 30 seconds

This mixed-method systematic review examined factors influencing implementation of exercise rehabilitation programs for patients with coronary heart disease (CHD). Searches covered databases from inception to June 1, 2024, and 21 studies were included. The review identified 18 facilitators and 16 barriers, organized across five Consolidated Framework for Implementation Research dimensions. Positive attitudes toward exercise were the most prevalent facilitator, while severe clinical conditions were the predominant barrier. Individual characteristics accounted for the largest share of both facilitators and barriers, with 9 and 8, respectively.

Key findings

  • Across 21 included studies, reviewers identified 18 facilitators and 16 barriers to implementing exercise rehabilitation for patients with CHD.
  • Positive exercise attitude was the most prevalent facilitator; severe clinical conditions were the predominant barrier.
  • Individual characteristics comprised the largest proportion, with 9 facilitators and 8 barriers.

Why it matters

Exercise rehabilitation programs may be effective, yet implementation challenges can restrict access and limit outcomes. Mapping barriers and facilitators across individual, organizational, and broader implementation dimensions helps clarify where program design and delivery may need attention. The review highlights patient-level factors in particular, while indicating that implementation requires consideration of multiple levels rather than a single obstacle.

What to keep in mind

The abstract does not report the number of participants or provide quantitative estimates of how strongly individual factors affected implementation.

Source

Published in J Cardiovasc Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.